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classified according to the categories of Chow (IJROBP, 
2012). 
Results: 248 consecutive patients (Male/Female: 144/104; 
median age: 68 years;range:27-94 years) were included in the 
study. On the basis of radiological exams and CT simulation, 
86% of the patients (214/248) had no extra-osseous extension 
compared to 14% (24/248) that presented bone disease with 
involvement of the adjacent soft tissues. All the patients 
were symptomatic for pain at the time of treatment. Three 
weeks later, 44% of the patients (109/248) showed pain 
reduction or resolution. In detail, 58 patients (23.5%) 
obtained a complete response (CR), 51 (20.5%) a partial 
response (PR), 63 (25%) no response to treatment (pain 
worsening) and 76 (30%) had an unspecified response. A 
statistically significant pain reduction was reported (pre- vs 
post-RT mean VAS: 4.6 versus 3.7; p=0.0001). CR rate (table 
1, p:0.678) as well CR+PR rate (p:0.274) were not 
significantly associated with extra-osseous extension. 
 
 
 
Conclusions: The efficacy of 8 Gy single fraction schedule 
was confirmed in terms of pain control even in patients with 
bone metastases with extension to soft tissues. The relatively 
low analgesic response is likely due to the administering of 
analgesic drugs before irradiation in the majority of cases. 
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Purpose/Objective: To evaluate and to compare the 
dosimetric features of static and volumetric intensity-
modulated radiotherapy (IMRT) for brain oligometastases 
hypofractionated stereotactic treatment, focusing on the 
dosimetric comparison between the single and multiple 
isocenters modalities for multiple contiguous brain 
metastases.  
Materials and Methods: Patients with single or multiple brain 
metastases, in the same lobe or contiguous, treated by 
hypofractionated stereotactic RT in our Institution were 
enrolled. For each patient 2 treatment plans were 
performed: a static (5 fields) and a volumetric (2 arcs) IMRT 
plans. For patient with multiple brain metastases, each plan 
was performed in 2 different modalities: single and multiple 
isocenters. The PTV was the lesion + 3 mm. In single 
isocentre modality plans, for patients with multiple lesions, 
the definitive PTV was the PTV sum of each single lesion. The 
prescribed dose to lesions was 25.5 Gy/3fr. Plans were 
evaluated for: monitor units (UM); Conformity Index (CI); 
Homogeneity Index (HI); Paddick Conformity Index (PCI); 
Gradient Index (GI); normal brain mean dose; brainstem, 
optic chiasm, optic nerves maximum dose; EQD2 
hyppocampus mean dose. Dose-volume histograms were 
compared by Friedman test. 
Results: Thirteen patients were included in the analysis, 7 
patients with a solitary lesion, 6 patients with multiple (2-3) 
metastases in the same lobe or contiguous, with a total of 20 
treated lesions. The median CTV was 0.71 cm3 (range, 0.21-
5.26), median PTV was 4.7 cm3 (range, 1.5-18.47). Median 
mean dose to normal brain tissue was 1.79 (0.68-6.27) for 
volumetric IMRT and 1.92 (0.69-8.70) for static IMRT (p: 
0.024). Among the 6 oligometastatic patients, a total of 13 
lesions was analyzed. For multiple isocenters modality plans 
median CTV was 0.53 cm3 (0.21-3.27), median PTV was 3.64 
cm3 (1.49-18.47). For single isocentre modality median CTV 
was 1.59 cm3 (0.47-5.95), median PTV 10.68 cm3 (2.99-
27.08). Median mean dose to normal brain tissue was 3.72 
(1.80-5.84) and 3.52 (2.49-5.67) for static IMRT in single and 
multiple modality, respectively, 3.84 (2.41-6.27) and 3.22 
(2.02-5.31) for volumetric IMRT in single and multiple 
isocentre modality, respectively (p:0.009). Median GI for 
static IMRT plans was 1.62 (1.40-2.05) and 1.50 (1.30-1.70) in 
single and multiple isocentre modality respectively, 1.60 
(1.25-1.95) and 1.35 (1.15-1.60) for volumetric IMRT plans in 
single and multiple isocentre modality respectively (p: 
0.024). None of the other studied parameters resulted in 
significant differences.  
Conclusions: In our experience static and volumetric IMRT 
are both efficient techniques for intensity modulated 
hypofracionated stereotactic treatment. Volumetric IMRT 
seems to results in lower normal brain dose in single 
isocenter modality; multiple isocenters modality seems to 
reduce normal brain irradiation in treating multiple 
contiguous lesions.  
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Purpose/Objective: Stereotactic Ablative Body Radiotherapy 
(SABR) has emerged as a novel treatment modality for local 
extracranial metastases such as lymph node oligometastases 
with promising clinical results. This study aims to investigate 
the relationship between dosimetric parameters of SABR and 
treatment outcomes for patients with unresectable nodal 
metastases. 
Materials and Methods: A retrospective review of SABR 
patients who were treated using a Cyberknife unit at our 
institution was carried out to determine each patient's 
Progression Free Survival (PFS) and Overall Survival (OS). 
Patient's demographic data including age, anatomical 
location of sites treated and histopathology of primary 
disease were reviewed. Assuming a/ß=10 for tumour control, 
dosimetric parameters including biological equivalent doses 
(BED) of prescription dose, minimum dose and mean dose to 
GTV and PTV (GTVmin, GTVmean, PTVmin and PTVmean) 
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from each patient's treatment plan were calculated. 
Spearman's rank correlation and multivariable regression 
analysis tested for association between the BEDs and the OS 
and PFS respectively. Of each BED, medians were used to 
split the distribution into two groups: above and below 
median for the Mann Whitney U test analysis.  
Results: Between September 2010 and March 2014, 33 
consecutive patients with unresectable nodal metastases 
were included in the study. The median of follow-up is 21.10 
months and the median of patient's age is 67.76 years old. 
Anatomical location of sites treated: Neck (n=2), Abdomen 
(n=19), and Pelvis (n=12). Histopathology of Primary: 
Colorectal (n=20), Breast (n=2), Urological (n=5), Gynae 
(n=2), and Other/Unknown primary (n=4). The medians and 
95% confidence intervals (CI) of OS, PFS, BED of prescription 
dose, GTVmin, GTVmean, PTVmin and PTVmean are 
summarised in table 1. 
 
 Median 95% CI 
OS (months) 19.03 15.39-22.74 
PFS (months) 12.27 10.88-17.64 
Prescription dose BED (Gy10) 51.30 52.48-60.72 
GTVmin BED (Gy10) 60.52 56.87-69.02 
GTVmean BED (Gy10) 78.41 74.76-90.39 
PTVmin BED (Gy10) 47.74 44.00-53.12 
PTVmean BED (Gy10) 69.57 67.62-79.65 
 
The results of the correlation analysis suggested that GTVmin 
(R=0.42, p<0.05) correlated to OS and PTVmin (R=0.48, 
p<0.05) correlated to PFS the most among all BEDs. Multiple 
linear regression analysis was used to develop a model for 
predicting OS and PFS from the dosimetric parameters. Both 
models for OS (F=2.04, df=5,27, p=0.11) and PFS (F=1.79, 
df=5,27 p=0.15) are not statistically significant. No significant 
differences were found in OS between the above and below 
median groups for all BEDs (p<0.05). Significant differences 
were found in PFS between the above and below median 
groups for all BEDs (p<0.05) apart from GTVmean BED 
(p=0.19).  
Conclusions: Our analysis of the data suggested that the 
level of dose received by tumours influenced PFS and this 
relationship was not found between the dosimetric 
parameters and OS. 
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Purpose/Objective: Many patients with advanced cancer 
develop bone metastases, with pain as a common and 
devastating consequence. Adequate treatment is important 
to maintain or improve quality of life (QoL). In 2002, an 
international consensus on palliative radiotherapy endpoints 
was established to improve comparability of trial results. 
Clinical trials using this consensus reported high response 
rates (60% using intention to treat (ITT) analysis, and up to 
80% in assessable patients only), indicating that palliative 
radiotherapy is an effective treatment. Clinical trials usually 
use strict inclusion criteria, resulting in selected patient 
groups and limited generalizability of results. The aim of this 
study is to estimate response to palliative radiotherapy in an 
unselected cohort of patients with bone metastases. 
Materials and Methods: Since June 2013, all patients with 
bone metastases requiring radiotherapy for pain or 
neurological complaints or for postoperative radiotherapy 
after fixation, who are treated at our department, are 
prospectively included in an ongoing cohort. Pain items using 
the Brief Pain Inventory and QoL variables using the PAL 15 
and BM 22 are obtained at baseline, and in weeks 4, 6 and 8 
following radiotherapy. For each patient, the best response 
outcome is calculated according to the international 
consensus criteria. Responders are patients with a complete 
or partial response, patients with pain increase, stable pain 
or undetermined response are regarded non-responders. 
Descriptive statistics were provided. Here we present the 
first outcome regarding pain outcome. 
Results: Until September 2014, 92% (n=238/258) of patients 
who were asked to participate were included. Patients 
requiring postoperative radiotherapy were excluded. Median 
age of the remaining 213 patients was 66 years (range 35-88). 
Median survival was 8 months (range 0-15 months). Most 
common primary cancer sites were prostate (31%), lung 
(25%), and breast (20%). 18 patients (9%) underwent 
radiotherapy because of neurological complaints. Median 
performance status as measured by KPS score was 70 (range 
20-100). Mean baseline pain scores at the irradiated sites was 
5.5 (SD + 2.6) with a median daily oral morphine equivalent 
dose intake of 74 mg (range 0-840 mg). Response rates of 176 
patients (83%) were available. 109 patients (62%) 
experienced a complete or partial response, whereas 67 
patients (38%) were classified as non-responders. However 
the ITT effect is lower: 51% of the patients experience pain 
relief (see table). 
 
 
Conclusions: The first response outcomes in this hospital 
based prospective cohort are lower than the response rates 
found in clinical trials. Continuous focus should be to predict 
which patients are most likely to respond, and which are not. 
We intend to proceed with the prospective data collection to 
be able to report on subgroup analyses, and QoL since 
